Early Evidence Showed THC Reduced Chemotherapy Nausea but Raised Safety Questions
A critical review of clinical studies found THC showed antiemetic promise for cancer patients undergoing chemotherapy, but identified significant gaps in understanding its clinical pharmacology and safety profile.
Quick Facts
What This Study Found
By 1981, both government and industry had invested substantial effort in isolating cannabis compounds with medical potential. THC's ability to reduce nausea and vomiting during cancer chemotherapy had emerged as one of the most active areas of investigation.
This review critically evaluated the clinical trial evidence for THC as an antiemetic, finding that while the drug showed efficacy, the evidence base had significant weaknesses. The reviewers identified deficiencies in understanding THC's basic clinical pharmacology, including absorption, metabolism, and dose-response relationships, that complicated evaluation of its safety and effectiveness.
Key Numbers
The review covered six years of research activity (approximately 1975-1981) across both government and private sector investigations.
How They Did This
Critical review of published clinical studies evaluating delta-9-THC as an antiemetic in cancer chemotherapy patients. The review assessed both efficacy and safety data.
Why This Research Matters
This review came at a critical juncture when THC was being seriously considered as a prescription medication. Its identification of pharmacological knowledge gaps helped shape the research agenda that eventually led to FDA approval of dronabinol (synthetic THC) in 1985.
The Bigger Picture
The trajectory from this 1981 review to dronabinol's 1985 FDA approval for chemotherapy-induced nausea shows how critical evaluation of early evidence can accelerate therapeutic development. Many of the pharmacological questions raised here were eventually addressed in the studies that supported approval.
What This Study Doesn't Tell Us
The review itself acknowledged that the evidence base had significant deficiencies. As a review from 1981, it predates decades of subsequent antiemetic research including modern serotonin antagonists that now dominate nausea management.
Questions This Raises
- ?How did the pharmacological gaps identified in this review get resolved in subsequent research?
- ?How does THC compare to modern antiemetics developed since 1981?
Trust & Context
- Key Stat:
- THC antiemetic research was among the most active areas of cannabinoid clinical research by 1981
- Evidence Grade:
- A critical review of clinical studies published in a pharmacy journal. Reviews synthesize existing evidence but are limited by the quality and quantity of available studies.
- Study Age:
- Published in 1981, four years before dronabinol received FDA approval. The antiemetic landscape has changed dramatically with newer drug classes.
- Original Title:
- A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.
- Published In:
- Drug intelligence & clinical pharmacy, 15(11), 867-75 (1981)
- Authors:
- Cocchetto, D M, Cook, L F, Cato, A E
- Database ID:
- RTHC-00017
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Did THC work against chemotherapy nausea?
The evidence showed efficacy, but the reviewers noted significant gaps in understanding THC's pharmacology that complicated safety and dosing assessments.
Did this lead to an approved medication?
Yes. Dronabinol (synthetic THC) was approved by the FDA in 1985 for chemotherapy-induced nausea, partly building on the evidence base reviewed here.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-cancer-pain-beyond-chemo-nausea
Cite This Study
https://rethinkthc.com/research/RTHC-00017APA
Cocchetto, D M; Cook, L F; Cato, A E. (1981). A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.. Drug intelligence & clinical pharmacy, 15(11), 867-75.
MLA
Cocchetto, D M, et al. "A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.." Drug intelligence & clinical pharmacy, 1981.
RethinkTHC
RethinkTHC Research Database. "A critical review of the safety and antiemetic efficacy of d..." RTHC-00017. Retrieved from https://rethinkthc.com/research/cocchetto-1981-a-critical-review-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.